CALCA and neuroendocrine neoplasm: For instance, it would be an option to explore the capacity of anti-CGRP therapeutics to control the diarrhea associated with neuroendocrine tumors such MTC, carcinoid and prostatic adenocarcinoma, in which the overexpression of CGRP results in elevated circulating levels of the peptide (Morris et al., 1984; Schifter et al., 1986; Takami et al., 1990; Shulkes et al., 1991; Hanna et al., 1997).